GenScipt Subsidiary Legend Biotech Finalizes Licensing Deal with Novartis for DLL3 CAR-T Therapies
GenScipt Biotech Corp., a China-based Contract Development and Manufacturing Organization (CDMO) (HKG: 1548), has announced...
CAR-T
JW Therapeutics and 2seventy Bio Ink Exclusive Deal for CAR-T Cell Therapy in Greater China
JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has announced an exclusive collaboration...
CATUG Biotechnology Partners with PersonGen to Advance Global CAR-T Cell Therapies
China-based CATUG Biotechnology (Suzhou) Co., Ltd. has entered into a partnership with fellow Suzhou firm...
Simcere Affiliate Shanghai Simnova Biotech Gets China Nod for CAR-T Therapy SNC109
Shanghai Simnova Biotech Co., Ltd, known as Simnova outside of China and an affiliate of...
AstraZeneca to Acquire China’s Gracell Biotechnologies in $1.2 Billion Deal
Pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced its intention to fully acquire Gracell Biotechnologies...
Legend Biotech’s Carvykti Therapy to Include Myeloid Neoplasms Warning in Label Update
GenScript Biotech Corporation (HKG: 1548), a China-based Contract Research Organization (CRO), has announced that its...
AbelZeta Pharma Expands Janssen Partnership to Include Commercial Rights in China
AbelZeta Pharma Inc., a Sino-US biotechnology company with operations in Rockville, Maryland, and Shanghai, China,...
J&J’s Carvykti Demonstrates Extended Time to Symptom Worsening in Multiple Myeloma Patients
Johnson & Johnson (J&J; NYSE: JNJ) has released data from a Phase III study showing...
CARsgen Therapeutics Halts Clinical Studies for Three CAR-T Therapies in the US Following FDA Request
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that the US Food and Drug...
Chinese Biotech Precision Biotechnology Gets NMPA Green Light for Advanced Cancer Therapies
Chongqing Precision Biotechnology Co., Ltd, a Chinese biopharmaceutical company, has received approval from the National...
CARsgen Therapeutics Secures U.S. FDA Approval for CT071 Clinical Trials in Multiple Myeloma
CARsgen Therapeutics Holdings Ltd (HKG: 2171), based in China, has announced that it has received...
CAR T-Cell Therapy Stocks Plunge as FDA Investigates Cancer Reports Linked to Treatments
Shares of Chimeric Antigen Receptor (CAR) T cell therapy companies plummeted on November 28, 2023,...
JW Therapeutics Secures Priority Review for Carteyva in Relapsed/Refractory Mantle Cell Lymphoma
JW Therapeutics (HKG: 2126), based in China, has announced that its CAR-T cell therapy, Carteyva...
Gracell Biotechnologies Gets FDA Green Light for FasTCAR-T Therapy in Systemic Lupus Erythematosus
Gracell Biotechnologies Inc., a Suzhou-based biotech company (NASDAQ: GRCL), has received approval from the US...
SCG Cell Therapy’s SCG101 Receives Tacit Approval for Cholangiocarcinoma Clinical Trial in China
China’s Center for Drug Evaluation (CDE) website has indicated that SCG Cell Therapy Pte. Ltd’s...
BMS and 2seventy Bio’s Abecma Faces FDA Review Extension
The US Food and Drug Administration (FDA) has postponed the target action date for Bristol...
Gilead’s Kite Expands Partnership with Arcellx for Innovative Cell Therapies
Gilead (NASDAQ: GILD), a leading biopharmaceutical company, has announced an expansion of its 2022 partnership...
CASI Pharmaceuticals Reports Q3 2023 Results with Mixed Fortunes and Positive Developments
China-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has unveiled its financial results for the third quarter...
Novartis Pharma AG Partners with Legend Biotech Corp. for CAR-T Therapies in $1.1 Billion Deal
China-based Legend Biotech Corp., (NASDAQ: LEGN) has secured a second multinational partnership for its chimeric...
China’s NMPA Grants Conditional Approval for Juventas’ CAR-T Therapy Inaticabtagene Autoleucel
The National Medical Products Administration (NMPA) has conditionally approved the marketing of inaticabtagene autoleucel (CNCT...